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Abstract 
The new 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Therapy (ART) make 
aspirational recommendations for ART delivery in low and middle income countries.  Comprehensive 
assessments of available evidence were undertaken and the recommendations made are likely to 
improve individual health outcomes.  However feasibility was downplayed, the Guidelines represent 
high-cost policy options not all of which are compatible with the core public health principles of 
decentralization; task-shifting; and a commitment to universality.   Critically, their impact on equity 
and the population-level distribution of health outcomes were not fully considered.  
 
We analyze the likely distribution of health outcomes resulting from alternative ways of realising the 
2013 Guidelines and assess practicality, feasibility and health attainment amongst different sections 
of the population in the context of financial and human resource constraints. Claim can be made 
that direct interpretation of the Guidelines follows a "human rights" based approach in seeking to 
provide individual patients with the best alternatives amongst those available on the basis of current 
evidence.  However, there lies a basic conflict between this and "consequentialist" public health 
based approaches that provide more equal population-level outcomes.  
 
When determining how to respond to the 2013 Guidelines and fairly allocate scarce lifesaving 
resources, national policymakers must carefully consider the distribution of outcomes and the 
underpinning social value judgements required to inform policy choice.  It is important to consider 
whose values should determine what is a just distribution of health outcomes.  The WHO Guidelines 
committees are well placed to compile evidence on the costs and effects of health care alternatives.  
However, their mandate for making distributional social value judgements remains unclear.   
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1. Introduction 
The recently released 2013 World Health Organization (WHO) Consolidated Guidelines on the Use of 
Antiretroviral Drugs for Treating and Preventing HIV Infection continue to inform global norms and 
standards guiding public sector approaches to ART treatment and care in HIV/AIDS epidemics in low 
and middle income countries(WHO 2013a).  The Guidelines were developed through a broad and 
consultative process in which four Guideline Development Groups (for Adults; Maternal and Child 
Health; Operational and Service Delivery; and Programmatic Issues) based their deliberations and 
ultimately decisions on evidence provided from multiple sources: systematic reviews and supporting 
evidence; modelling and cost-effectiveness studies; and community values and preferences. The 
importance of three core principles of the public health approach to ART (Gilks et al. 2006) were 
highlighted: standardisation of therapy into first and second line regimens; simplification of patient 
monitoring and treatment approaches; and decentralisation through task-shifting of simplified and 
standardised ART delivery.  The main target audience of the Guidelines remains national planners 
and policymakers. The breadth of work that went into the development of the Guidelines is 
impressive and the team in charge of the process deserve praise.  
 
The key differences between the previous 2010 and the new 2013 Guidelines are summarized in 
Table 1.  Broadly, the recommendations that have been revised are those that appear to be both the 
most effective for the treatment of patients and for the reduction in onward HIV transmission to 
partners on the basis of current clinical evidence.  It should be noted however that the quality of 
clinical evidence for modifying the previous recommendations (WHO 2006; WHO 2010) is generally 
low, and that all the new recommendations come with significant additional costs. 
 
Table 1: Key new recommendations in 2013 WHO consolidated HIV treatment guidelines 
Topic 
2010 WHO Guideline 
Recommendations 
2013 WHO Guideline 
Recommendations 
Quality of evidence 
supporting 
recommendations 
When to start antiretroviral 
therapy 
 ?A䜀  ? ? ?- Irrespective CD4  
for TB & HBV 
 ?A䜀  ? ? ? Moderate quality 
evidence 
Patient monitoring 
when on ART 
Clinical or CD4 monitoring 
Phase in of viral load testing 
Viral load monitoring Low quality evidence 
PMTCT Interventions Option A (AZT +infant NVP) 
Option B (triple ARVs)  
Lifelong ART for all 
pregnant or 
breastfeeding women 
irrespective of CD4  
count (Option B Plus) 
Low quality evidence 
When to start ART  
in children 
ART initiated in all children under 
two years of age - Irrespective CD4 
ART initiated in all 
children under five years 
of age - Irrespective CD4 
Very low quality evidence 
Paediatric 1
st
 line ARVs NNRTI based regimen PI based regimen - 
regardless of NNRTI 
exposure  
Moderate quality 
evidence 
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In selecting these particular approaches, from amongst all others that could have been 
recommended, the Guidelines send a clear statement of intent of seeking to close the gap between 
what is available for patients treated in the public sectors of low and middle income countries and 
the interventions patients typically receive with state support in higher income settings. This 
ĚĞĐŝƐŝŽŶƚŽ ?ĐůŽƐĞƚŚĞŐĂƉŝŶƐƚĂŶĚĂƌĚƐ ?ŚĂƐďĞĞŶǁŝĚĞůǇǁĞůĐŽŵĞĚďǇƐƉĞĐŝĂůŝƐƚƉƌĂĐƚŝƚŝŽŶĞƌƐ ?ƉĂƚŝĞŶƚ
groups and advocates, particularly those from North America and Europe.  However, not much 
attention has been given to the very different way in which ART is delivered in higher income 
settings, where physician choices dictate which initial and subsequent regimens are prescribed and 
how individual patients are then monitored - in contrast to the protocol and guideline-driven public 
health approaches routinely followed in resource-limited settings. In particular, it remains unclear 
how these approaches can be adapted to facilitate decentralisation and task-shifting  W both critical 
to enable universal access to ART in resource constrained settings with few specialist physicians or 
well-equipped laboratories and patients having to travel large distances to access higher level health 
facilities at their own expense.  
 
The 2013 Guidelines place additional demands (in terms of both human resources and financial 
costs) on health care systems already facing severe resource constraints and with other competing 
and equally compelling health priorities. Estimates of the financial costs of implementing the 
Guidelines remain uncertain (WHO 2013a; Eaton et al. 2014), but adopting the increase in the adult 
eligibility criteria alone has been estimated to increase the number of adults in need of ART globally 
from 16.7 to 25.9 million (Sabin et al. 2013). Currently there are an estimated 10 million people on 
ART globally, with coverage in sub-Saharan Africa of those classified as being in need based on 
previous (2010) WHO Guidelines (WHO 2010), being only 68% for adults (with CD4<350) and 32% for 
children (UNAIDS 2013). Coverage is even lower in some other regions with emerging epidemics (e.g. 
22% coverage for adults in North Africa and the Middle East; 35% in Eastern Europe and Central 
Asia). Coverage estimates are based on the ratio of those on treatment to those in need (WHO 
2013c) and hence risk portraying too rosy a picture of successes in scaling up ART since those 
without access die more quickly (and therefore reduce the denominator). 1 
 
The 2013 Guidelines are regarded as aspirational, aiming to drive further progress in access to high-
quality and effective ART management for all who need treatment. However, the current inability of 
health care systems in low and middle income countries under the greatest burdens from HIV/AIDS 
to fully meet the treatment needs of their HIV infected populations brings into sharp focus 
distributional concerns related to the allocation of future HIV/AIDS resources, and how different 
policy decisions may affect the distribution of health benefits resulting from ART. The evidence 
incorporated into the Guidelines therefore needs to be assessed together with an awareness of 
social value judgements that policy choices based on the new recommendations would imply. The 
clinical and cost-effectiveness modelling and stakeholder consultation evidence informing the 
recommendation is reported in the Guidelines and elsewhere (WHO 2013a; Eaton et al. 2014; 
Keebler et al. 2014; WHO 2013b) (see Appendix for a brief summary). Results from the cost-
effectiveness modelling exercises examining the costs and health benefits expected with different 
eligibility and monitoring policy choices are summarised in Table 2.  In this paper our focus is on the 
role of social value judgements in supporting alternative ways in which HIV programme planners in 
resource limited settings could respond to the 2013 Guideline recommendations. 
                                                 
1
 Perhaps a better metric would be the proportion of those in need of ART over the last five years (including those died) 
who are currently alive on ART. 
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Table 2: Recommendations from modelling and cost-effectiveness studies 
Modelling and cost-effectiveness study topics Main conclusions 
Cost-effectiveness of alternative expansions 
of eligibility criteria 
On the basis of assessing current uncertain evidence, raising 
the adult eligibility criteria to initiate ART from CD4<350 to 
<500 is expected to generate health benefits for patients on 
ART and reduce onward HIV transmission as long as all 
patients currently in care with CD4<350 are currently on ART.  
If the choice is between increasing the eligibility criteria from 
CD4<350 to CD4<500 cells for those currently in care, or 
expanding testing and linkage to care so that 80% of those in 
need at CD4<350 are identified and receive ART then 
increasing the eligibility criteria is likely to be cost-effective. 
However, there may be intermediate levels of resource 
availability in which prioritizing testing leads to greater 
population health gains (Eaton et al. 2014).
 
Cost-effectiveness of alternative approaches 
to monitoring patients on ART 
Routine viral load testing is expected to be the most effective 
monitoring strategy for individuals on ART but comes at very 
high cost and set up costs are likely to be significant. Countries 
can be expected to maximize health gains by prioritizing 
expansion of ART to close to full coverage, firstly at eligibility 
criteria of CD4<350 and then at CD4<500, using existing or 
strengthened services for CD4 testing and clinical monitoring. 
Viral load monitoring is not expected to be cost-effective at 
current costs as long as gaps in ART coverage remain (Keebler 
et al. 2014).   
 
4  CHE Research Paper 99 
2. Distributional concerns and notions of social justice 
Fairly allocating scarce lifesaving healthcare is an area in which un-ĐŽŶƚĞŶƚŝŽƵƐ ?ĐŽƌƌĞĐƚ ?ĂŶƐǁĞƌƐĐĂŶ
rarely be found. It is important to recognise that determining which choices should be assessed as 
 ?ĨĂŝƌ ? ĂƌĞ ŶŽƚ ĂŶĂůǇƚŝĐĂů ŝƐƐƵĞƐ ƚŚĂƚ ĐĂŶ ďĞ ƌĞƐŽůǀĞĚ ďǇ ƚŚĞ ŵĂƚŚĞŵĂƚŝĐĂů ŵŽĚĞůƐ ĂŶĚ quantitative 
methods alone, rather they are social value judgements that may differ across individuals and 
populations (Culyer 2006). 
A number of notions of distributive justice can be invoked to support alternative population health 
outcome profiles (Williams & Cookson 2000). We highlight and explain three contrasting approaches 
that may result from decision makers in resource constrained settings responding to the new 2013 
HIV Treatment Guidelines. It is important to note that these are in no way exhaustive, and in fact 
represent just three points along a spectrum of alternative viewpoints. Figure 1 shows the remaining 
life expectancy of those infected with HIV or at greatest risk of infection split by population quintiles 
ŽŶƚŚĞďĂƐŝƐŽĨ ?ĞĂƐĞŽĨƌĞĂĐŚ ?ƚŽĚĞůŝǀĞƌƌĞƋƵŝƌĞĚ,/sŝŶƚĞƌǀĞŶƚŝŽŶƐ ?ŝ ?Ğ ?ƚŚŽƐĞŝŶĐĂƌĞĂŶĚŝŶĞĂƐŝůǇ
reachable urban locations are located on the left side of the plots; those out of care and/or in harder 
to reach rural locations are on the right.  It is likely that those in harder to reach locations are also 
socio-economically more disadvantaged).  The overall mean remaining life expectancy under each 
scenario, across representative populations in low or middle income countries, is also shown. While 
the plots in Figure 1 are stylised to highlight the trade-offs inherent in the alternative 
implementations of the Guidelines, they broadly reflect the evidence from the modelling studies 
used to inform the guideline development process (see Appendix and Table 2).  
Our first interpretation of the 2013 Guidelines largely follows the human rights based approach. 
EĂƚŝŽŶĂů ƉŽůŝĐǇŵĂŬĞƌƐ ĐŽƵůĚ ĨŽůůŽǁ ƐƉĞĐŝĂůŝƐƚ ĐůŝŶŝĐŝĂŶ ĂĚǀŝĐĞ ĂŶĚ ĐŚŽŽƐĞ ƚŽ ƉƌŽǀŝĚĞ ƚŚĞ  ?ďĞƐƚ ?
interventions, judged as the interventions that offer the greatest benefits compared to other 
alternatives to an individual patient and their immediate associates.  By implication, however, given 
ŚƵŵĂŶĂŶĚĨŝŶĂŶĐŝĂů ƌĞƐŽƵƌĐĞĐŽŶƐƚƌĂŝŶƚƐ ? ŝƚ ŝƐ ŝŵƉŽƐƐŝďůĞƚŽƉƌŽǀŝĚĞƚŚĞ  ?ďĞƐƚ ? ŝŶƚĞƌǀĞŶƚŝŽŶs to all 
those in need, thereby leaving many in the population with nothing more than the most basic care 
(Daniels 1993). This approach is implied by direct implementation of the new WHO 2013 Guidelines 
favouring a group of patients who could receive more individualised physician care, start ART earlier 
(based on CD4 threshold) and be supported by viral load monitoring. Although it may be deemed 
ethical to close the gap in treatment approaches between higher and lower/middle income 
countries, within a jurisdiction such an approach is usually incompatible with universal service 
provision and can lead to highly unequal outcomes. This is depicted in Figure 1(a); where we see the 
easiest to reach groups in the population achieve notable gains in remaining life expectancy, whilst 
the hardest to reach groups remain with very poor access to HIV testing and ART, resulting in an 
overall mean remaining life expectancy of 15 years in the population. 
Figure 1: Distribution and sum total of remaining life expectancy arising from alternative social value 
judgements in implementing the new Guidelines 
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A claim to distributive justice, predicated on a fair process by which to select those that receive the 
best treatment available, can be made following this approach. A commonly cited example of one 
ƐƵĐŚ ĨĂŝƌ ƉƌŽĐĞƐƐ ŝƐ Ă ůŽƚƚĞƌǇ ŝŶ ǁŚŝĐŚ ĂŶ ŝŶĚŝǀŝĚƵĂů ?ƐĐŚĂŶĐĞƐ ŽĨ ƌĞĐĞŝǀŝŶŐ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ĚŽ ŶŽƚ
depend upon their personal circumstances such as their socio-economic status or proximity to a 
national centre of excellence (Broome 1984), (Harris 1996). However, in practice, instead of a fair 
lottery, access is often allocated according to first come first served criteria, often based upon 
geographical location that tends to reinforce existing inequities in societies (Daniels 2004).   
Our second interpretation of the 2013 Guidelines follows a utilitarian approach, as is usually adopted 
in cost-effectiveness analysis. Society may choose to maximize aggregate population health 
ƌĞŐĂƌĚůĞƐƐŽĨǁŚŽŐĂŝŶƐĨƌŽŵŝŶƚĞƌǀĞŶƚŝŽŶƐƉƌŽǀŝĚĞĚ ?ŝ ?Ğ ?ƚĂŬŝŶŐƚŚĞƐƚĂŶĐĞƚŚĂƚ ?Ă>z-averted is a 
DALY-ĂǀĞƌƚĞĚ ? ƌĞŐĂƌĚůĞƐƐ ŽĨ ƚŽ ǁŚŽŵ ŝƚ ĂĐĐƌƵĞƐ ? ? tŚŝůƐƚ ƚŚŝƐ ĂƉƉƌŽĂch is often assumed to be 
distribution invariant, it also implies a value judgement in allocating health care resources to those 
in whom there is the highest capacity to benefit per dollar spent (Culyer & Wagstaff 1993). Although 
this approach will generally result in more equal health outcomes, particularly compared to a 
lottery, fully equalized outcomes are unlikely to occur. Inequalities are notably likely to remain if 
some people with the worst health outcomes have low capacity to benefit and/or if providing 
interventions to some members of the population is particularly expensive or impractical (e.g. in 
remote and underserved areas). This approach is depicted in Figure 1(b). We see from the figure 
that while no group in the population benefits as much as those receiving the highest levels of care 
available under the lottery approach, health gains are spread across the population resulting in a 
higher overall mean remaining life expectancy of 16 years.  In practice, a distribution of this type  is 
most likely to result from a  public health approach predicated on decentralisation, task-shifting,  
limited focussed CD4 laboratory monitoring (at least to prioritise ART initiation), and wide access to 
first and second-line ART (i.e. continuing the approaches currently contained in many low and 
middle income counties national ART guidelines and policies (WHO 2010; UNAIDS 2013; Kessler & 
Braithwaite 2013).   
The final interpretation of the 2013 Guidelines we consider is where society chooses to focus efforts 
on improving the lot ŽĨ ƚŚĞǁŽƌƐƚŽĨĨ ŝŶ ƚŚĞƉŽƉƵůĂƚŝŽŶ ?ĂŶĚ ƚŚĞƌĞďǇĂĚŽƉƚƐĂ  ?ŵĂǆŝŵ Ŷ ?ƉƌŝŶĐŝƉůĞ 
(Rawls 1971).  This implies concentrating resources on those expected to have the worst health 
outcomes regardless of their capacity to benefit and/or the costs faced to improve their health 
(Parfit 1997).  Although this position is likely to ultimately lead to the most equal outcomes, because 
resources are finite, maximizing the lot of the worst off is often achieved only at the expense of 
notably reducing average health outcomes in the population (Hauck et al. 2002).  Society must 
therefore decide the extent to which more equal outcomes should be achieved at the expense of 
reduced outcomes on average (Williams & Cookson 2006). This approach is depicted in Figure 1(c); 
we see that remaining mean life expectancy is distributed much more equally than under the other 
two approaches with greater health gains accruing to the hardest to reach groups. Overall mean 
remaining life expectancy under this approach is 14 years.  This would be an extreme egalitarian 
position that is often hard to attain in practice, particularly in the lowest income countries with high 
income inequality and weak health systems. 
A distribution of type depicted in 1(c) is very probably incompatible with the 2013 Guidelines, and 
even the 2010 Guidelines, in virtually all low and middle income countries. It could potentially be 
achieved by making a clear policy commitment to provide a basic universal package of HIV treatment 
and care  W predicated on decentralisation, expanded testing, further task-shifting, use of clinical 
monitoring only, limiting eligibility to CD4<200 and only providing lower cost ARV regimens (i.e. the 
rather minimalist approaches in the 2006 Guidelines).  It would also require substantial resources be 
devoted to implementation initiatives and perhaps incentives to retain patients in care. However, 
policy-makers would have to be willing to face potential reductions in overall population health to 
ensure benefits are realized by the hardest to reach. 
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3. Interpreting the 2013 guidelines for national level policy-making 
The 2013 WHO Consolidated HIV Treatment Guidelines represent a clear, indeed aspirational, 
statement of intent on the future direction of HIV treatment responses. Perhaps the most notable 
feature of the recommendations are that alternatives have been chosen that are deemed by the 
Guidelines Committees to be the most effective for individual patients on the basis of current but  
uncertain evidence despite being extremely high cost. The recommendations are likely to align most 
closely with the lottery-type distribution of health outcomes, although most probably on a first-
come first-served basis relating to geographical ease of reach. They appear motivated by a desire to 
close the gap in the perceived quality of treatment available at the individual patient level between 
low and middle income countries and high income settings. However, within a particular jurisdiction 
- with existing gaps in service provision, access, and treatment coverage - their immediate 
implementation is likely to result in highly unequal health outcomes.  
It should be noted that the 2013 Treatment Guidelines represent just the next step in a continuous 
process of updating the evidence base and evolving global norms and standards for ART delivery. 
They are intended to be followed by Programmatic Guidelines that tailor the recommendations to 
the prevailing situations in individual countries in order to update existing policies and National 
Guidelines. Nevertheless, the Consolidated Guidelines outline recommendations intended in some 
ǁĂǇ ƚŽ ďĞ  “ƉƌŽŐƌĞƐƐŝǀĞůǇ ƌĞĂůŝƐĞĚ ? ďǇ ĐŽƵŶƚƌŝĞƐ ? tŚĞŶĚĞǀĞůŽƉŝŶŐ ƚŚĞŝƌ ŽǁŶ ƉůĂŶƐ national 
policymakers may find it difficult to substantially divert from what may become regarded as 
international standards, particularly if international donors were to make funding contingent on how 
closely country programmes adhere to the recommendations.  The direct adoption of the 2013 
Guidelines, without consideration of distributional effects within jurisdictions, could have tragic 
consequences for the many in need but not currently receiving ART. 
In this paper we have outlined three notions of social justice, along a wider spectrum, that can be 
invoked when determining the appropriate expansion path for HIV/AIDS treatment programmes in 
low and middle income countries in response to the 2013 Guideline recommendations. We have 
also considered feasibility, particularly in the context of limitations in financial and human resources. 
EŽŶĞŽĨƚŚĞƐĞĂƉƉƌŽĂĐŚĞƐĂƌĞƵŶĞƋƵŝǀŽĐĂůůǇ ?ƌŝŐŚƚ ?Žƌ ?ǁƌŽŶŐ ?, instead they rely upon the values of 
constituents to inform which decisions can be perceived as just.  
An important question is therefore whose values should determine what is a just distribution of 
health outcomes. There appear to be at least three valid constituents to inform allocations within a 
particular jurisdiction: (1) Officials in national bodies with mandate for oversight of HIV programmes 
and/or national budgets (e.g. Ministries of Health, Finance, elected representatives) clearly have a 
valid claim; (2) Where a substantial amount of funding is from donor commitments (e.g. bilaterally 
from the Presidents Emergency Plan for AIDS Relief (PEPFAR), or multilaterally from the Global Fund 
ĨŽƌ/^ ?dĂŶĚDĂůĂƌŝĂ ?'&dD ? ? ?ƚŚĞŶŝƚƐĞĞŵƐƌĞĂƐŽŶĂďůĞƚŚĂƚĨƵŶĚĞƌƐ ?ǀĂůƵĞƐƐŚŽƵůĚĂůƐŽŚĂǀĞ
some bearing over distributive decisions; and (3) People living with HIV, at risk of HIV, and  more 
generally citizens within a jurisdiction where the guidelines will be implemented, also have a claim 
that their preferences be taken into account even if they do not usually have the same power as 
politicians, national authorities or funders to directly influence allocation decisions.  Caution should 
however be exercised in reflecting the values of patient groups comprising only those currently on 
ART since such groups may be parochial and only value health gains to those currently on ART and 
not the wider population in need.  
Whilst the WHO guidelines committees are groups tasked with interpreting the evidence and 
deriving recommendations, it is important to be cognisant that this task implicitly involves making 
distributional social value judgements.  Since the committees are not directly accountable to those 
in need of ART within jurisdictions, nor do they directly provide funding, their mandate for making 
these value judgements remains unclear.  
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4. Conclusion 
We have argued in this paper that distributional social value judgements were made in deriving the 
2013 WHO ART Guidelines and likewise need to be made by countries in deciding how to implement 
them. Whilst the most direct reading of the Guidelines would suggest a lottery approach be taken 
when implementing them, in many situations there is likely to be a strong preference from 
constituents for pursuing more inclusive and universal approaches. Policymakers within particular 
jurisdictions must carefully consider both the distribution of outcomes likely to result from how they 
respond to the Guidelines and the process by which to assess whether alternative distributions align 
ǁŝƚŚƐŽĐŝĞƚĂůŽďũĞĐƚŝǀĞƐ ? “DŽƌĞŽĨƚŚĞƐĂŵĞ ?ŽƌĞven greater emphasis on the needs of the harder to 
reach, through continuing to roll out and increasing ART coverage using a clear public health 
approach already implicit in current national ART policies in most countries may be preferable to the 
selective adoption of a more individualised approach which can only benefit the few and risks 
reinforcing existing inequities in access to ART and associated care. 
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Supplementary appendix 
Review of evidence 
The 2013 World Health Organization Consolidated Guidelines for HIV Treatment were developed 
through a broad and consultative process in which four Guideline Development Groups (for Adults; 
Maternal and Child Health; Operational and Service Delivery; and Programmatic Issues) based their 
deliberations and ultimately decisions on evidence provided from multiple sources (systematic 
reviews and supporting evidence, modelling and cost-effectiveness studies, and community values 
and preferences).  The evidence on which the Guidelines were based is briefly assessed here. 
 
1. Clinical effectiveness of guideline interventions 
The Guideline Development Groups placed a primary focus on evidence supporting the clinical 
effectiveness of alternatives under consideration. Evidence on clinical effectiveness was based on 
systematic reviews that followed the Population, Interventions, Comparisons and Outcome (PICO) 
format. The quality of evidence was then assessed using a standardized Grading of Recommendation 
Assessment, Development and Evaluation (GRADE) approach (WHO 2013a), (Guyatt et al. 2011). The 
quality of evidence behind the key recommendations was moderate at best (Sabin et al. 2013). 
 
Despite the concerns about the quality of the evidence and the lack of practical considerations about 
scale-up and decentralised implementation, there did appear to be general clinical consensus that 
the recommendations contained in the Guidelines were effective alternatives for treating patients 
and reducing onward transmission. Interestingly, there was no evidence that the existing public 
health approach was inferior to individualised specialist care in terms of survival or retention in care.  
 
2. Modelling and cost-effectiveness studies 
All of the 2013 recommendations represent high cost strategies with considerable human resource 
implications: increasing the eligibility criteria implies additional treatment costs of treating those 
with CD4 between 350 and 500 at a cost of >$100 per patient year; monitoring patients with viral 
loads is likely to cost around $45 per test as compared to $12 per test when using CD4 tests or 
simply the cost of a clinic visit with clinical assessment (Keebler et al. 2014) and requires a quantum 
increase in laboratory technology as well as technicians; lifelong ART means providing expensive 
ARVs to mothers not in clinical need of ART between and after pregnancies; and switching to a LPV/r 
paediatric ARV regimen from an NNRTI based regimen would raise the costs of paediatric ARVs 
approximately three-fold  (Prendergast et al. 2012) as well as adding considerable logistic challenges 
in drug supply chains (as this drug is available for infants only as a syrup requiring cold chain) and 
also further  complexity for viable second-line options. The new Guidelines will also prove more 
challenging in terms of achieving universal access through wider decentralisation and deeper task-
shifting because they require more rather than less specialist care, physician contact and supporting 
laboratory infrastructure.  
 
Given both the potential increase in effectiveness and evident increase in cost implied by the 
recommendations in the 2013 Guidelines, two major cost-effectiveness studies were undertaken by 
several modelling groups, under the umbrella of the HIV Modelling Consortium, on: (1) alternative 
eligibility criteria for adults; and (2) alternative adult patient monitoring strategies (see Table 2 for 
the main results) (Keebler et al. 2014), (Eaton et al. 2014). The analyses took as their objective the 
mĂǆŝŵŝǌĂƚŝŽŶŽĨƉŽƉƵůĂƚŝŽŶŚĞĂůƚŚĨƌŽŵĂǀĂŝůĂďůĞƌĞƐŽƵƌĐĞƐ ?ƌĞŐĂƌĚůĞƐƐŽĨǁŚŽŵĂĚĚŝƚŝŽŶĂů ?ŚĞĂůƚŚ ?
accrues to (health was measured in terms of disability adjusted life years (DALYs) averted). Despite 
this lack of distributional focus both studies highlighted the importance of equity concerns and 
recommended these should be an important additional consideration in the formulation and 
interpretation of the Guidelines. 
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3. Community values and stakeholder preferences 
The development of the Guidelines was undertaken in a consultative manner with input sought from 
people living with HIV/AIDS, community representatives, health care workers, national decision-
makers and international funders. Extensive work in particular was focused on understanding 
stakeholder values and preferences. This work stressed a rights based approach in which access to 
health interventions that can lead to health improvement for patients was seen as a fundamental 
human right that must be provided. However it also recognised that in the context of resource 
constraints it is likely that priority will often have to be given to those who are most ill and not 
currently on ART, who cannot routinely visit a physician or access laboratory services. 
 
